ERBB2 and breast carcinoma: While most trials in the first time-period included all breast cancers without any limitation to any given biological subgroup, the majority of trials published between 2016 and 2020 focused on one large intrinsic subgroup (ER positive–HER2-negative BC; HER2-positive BC; or triple negative BC).